Interaction Checker

Interaksi Bendamustin

Bendamustin (Treanda, Bendeka, Belrapzo) memiliki 91 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 2 mayor, 89 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (2)

  • Alopurinolpenghambat xantin oksidaseMayor

    However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly. [see Warnings and Precautions (5.6) ] 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride injection treatment in clinical trials and postmarketing safety reports, including… (label Bendamustin, Peringatan dan perhatian)

  • RituksimabimunosupresanMayor

    Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions (6.2) ] . (label Bendamustin, Peringatan dan perhatian)

Interaksi moderat (89)

  • AbataseptimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • Abrositinibpenghambat JAKModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • AdalimumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • AlemtuzumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • AzatioprinimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • AzelastinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Barisitinibpenghambat JAKModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Bromfeniramin, pseudoefedrin, dan dekstrometorfanantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Deferasirokssuplemen zat besiModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • DeflazakortkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DeksametasonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DeksklorfeniraminantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DesloratadinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DifenhidraminantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • DimenhidrinatantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Dimetil fumaratimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • DoksilaminantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Doksilamin dan piridoksinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • EtanerseptimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • EverolimusimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • FeksofenadinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • FingolimodimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • FluvoksaminSSRIModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • GuselkumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Hidrokodon dan klorfeniraminopioidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • HidroksizinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • InfliksimabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • Kanabidiol (obat resep)antikonvulsanModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • KarbamazepinantikonvulsanModerat

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (label Bendamustin, Interaksi obat)

  • KarbinoksaminantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • KladribinantimetabolitModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • KlemastinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • KlorfeniraminantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • LeflunomidimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • LevosetirizinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Lopinavir dan ritonavirantiretroviralModerat

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (label Bendamustin, Interaksi obat)

  • LoratadinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • MeklizinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • MeksiletinantiaritmiaModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • MerkaptopurinantimetabolitModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • MetotreksatimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • MikofenolatimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • NatalizumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • OkrelizumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • OlopatadinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Pimekrolimuspenghambat kalsineurinModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • PonesimodimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Ritlesitinibpenghambat JAKModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • RitonavirantiretroviralModerat

    Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (label Bendamustin, Interaksi obat)

  • SekukinumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • SetirizinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • SiklofosfamidimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • Simetidinpenghambat H2Moderat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • SiproheptadinantihistaminModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • SirolimusimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • TakrolimusimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • TeriflunomidimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • TofasitinibimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • TosilizumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • UpadasitinibimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • UstekinumabimunosupresanModerat

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (label Bendamustin, Peringatan dan perhatian)

  • Viloksazinpenghambat ambilan kembali norepinefrinModerat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

  • Zileutonpenghambat CYP1A2Moderat

    Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of Bendamustine Hydrochloride Injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with Bendamustine Hydrochloride Injection [see Clinical Pharmacology (12.3) ] . (label Bendamustin, Interaksi obat)

Periksa Bendamustin terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.